
AL constitutes over 80% of Artemisinin Combination Therapy (ACT) procured under Global Fund and other similar programs. The benefits of ACTs are their high efficacy, fast action and reduced likelihood of resistance developing. WHO currently advises that all malaria cases should be treated with ACT.

Over 300 million new malaria cases were reported in Africa alone in 2011. It is estimated that only about 10% of the actual incidence gets reported. ACT procurement plan for 2013 is estimated to be in the region of $ 450 million.

Commenting on the development, Manish Gupta, CEO-Pharma, Strides Arcolab stated – “This approval is another initiative by Strides to make high quality, affordable medicines available in the African sub-continent and other middle-income countries and compliments our basket of products in the anti-HIV/AIDS and anti-TB therapies for these markets.

With this approval, Strides becomes the only player to provide complete treatment portfolio in the major diseases of HIV, TB and malaria, which continue to plaque the low and middle-income countries.

The product will be manufactured at our US-FDA approved and WHO pre-qualified facility in Bangalore. The supplies of the product will commence immediately.
About Artemether+Lumefantrine (AL)

Artemether+Lumefantrine Tablets 20/120mg is a fixed-dose combination indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria. The development and manufacturing of this fixed dose combination is challenging due to complex bio-equivalence, stability and manufacturability of the product.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Manish Gupta, CEO - Pharma +91 80 6784 0112</td>
<td>Corporate Voice</td>
</tr>
</tbody>
</table>
| Mr. Kannan N : +91 98450 54745 (Investors) | Mahesh Nair,  
+91 98803 76648  
maheshn@corvoshandwick.co.in |
|                            | Kaveri Mandanna,  
+91 90089 59697  
kaveri@corvoshandwick.co.in |